We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
In the latest trading session, Boston Scientific (BSX - Free Report) closed at $38.60, marking a +0.42% move from the previous day. This change outpaced the S&P 500's 0.92% loss on the day. At the same time, the Dow lost 0.77%, and the tech-heavy Nasdaq lost 1.65%.
Heading into today, shares of the medical device manufacturer had gained 6.78% over the past month, outpacing the Medical sector's loss of 0.56% and the S&P 500's loss of 2.56% in that time.
Wall Street will be looking for positivity from BSX as it approaches its next earnings report date. This is expected to be February 7, 2019. On that day, BSX is projected to report earnings of $0.36 per share, which would represent year-over-year growth of 5.88%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.56 billion, up 6.17% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $1.39 per share and revenue of $9.83 billion, which would represent changes of +10.32% and +8.64%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for BSX. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.39% higher within the past month. BSX currently has a Zacks Rank of #3 (Hold).
Investors should also note BSX's current valuation metrics, including its Forward P/E ratio of 27.58. This valuation marks a premium compared to its industry's average Forward P/E of 26.06.
Also, we should mention that BSX has a PEG ratio of 2.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BSX's industry had an average PEG ratio of 2.37 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BSX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Boston Scientific (BSX) Gains As Market Dips: What You Should Know
In the latest trading session, Boston Scientific (BSX - Free Report) closed at $38.60, marking a +0.42% move from the previous day. This change outpaced the S&P 500's 0.92% loss on the day. At the same time, the Dow lost 0.77%, and the tech-heavy Nasdaq lost 1.65%.
Heading into today, shares of the medical device manufacturer had gained 6.78% over the past month, outpacing the Medical sector's loss of 0.56% and the S&P 500's loss of 2.56% in that time.
Wall Street will be looking for positivity from BSX as it approaches its next earnings report date. This is expected to be February 7, 2019. On that day, BSX is projected to report earnings of $0.36 per share, which would represent year-over-year growth of 5.88%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $2.56 billion, up 6.17% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $1.39 per share and revenue of $9.83 billion, which would represent changes of +10.32% and +8.64%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for BSX. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. The Zacks Consensus EPS estimate has moved 0.39% higher within the past month. BSX currently has a Zacks Rank of #3 (Hold).
Investors should also note BSX's current valuation metrics, including its Forward P/E ratio of 27.58. This valuation marks a premium compared to its industry's average Forward P/E of 26.06.
Also, we should mention that BSX has a PEG ratio of 2.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. BSX's industry had an average PEG ratio of 2.37 as of yesterday's close.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 107, which puts it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow BSX in the coming trading sessions, be sure to utilize Zacks.com.